Stock Ratings / Health Care / MTEX / earnings

BON (45) NAII (34) BTMD (62) FTLF (48) ⌘ Pro Terminal →

Mannatech Incorporated (MTEX) Next Earnings Date & Expected ±12.5% Move

$8.33 -2.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Mannatech Incorporated (MTEX) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $16.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MTEX)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.04 Expected Swing

MODEL EARNINGS SETUP GAUGE

MTEX Quantitative Pre-Earnings Setup: 33/100

Trailing EPS: $4.25 • YoY Revenue Growth: -8.3%

Model Bullish Setup (33/100)Model Risk Weight (67/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$108.0M	-$15.2M	-$4.3M	74.9%
FY 2024	2024-12-31	$117.9M	$2.5M	$2.0M	77.6%
FY 2023	2023-12-31	$132.0M	-$2.2M	-$2.4M	74.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MTEX)

✓Walkthrough of MTEX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MTEX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +90.18%▲ ASCENDING CHANNEL

2026-10-30O $8.48H $8.67L $8.33C $8.33VOL 23.1K

RES: $12.02SUP: $7.23SMA50: $7.69SMA200: $6.29

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MTEX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MTEX Butterfly Map → + Track MTEX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -8.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MTEX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MTEX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MTEX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MTEX)

Health Care Rank #878 of 1016 ⚔️ BON vs MTEX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MTEX vs. BON, NAII, BTMD, FTLF)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Mannatech Incorporated (MTEX) ranks #878 by composite RQD confidence (33/100, grade E) and #853 by equity capitalization ($16.1M). Within this direct 5-issuer industry benchmark cohort, FTLF leads on earnings valuation at 11.7x trailing P/E, while BTMD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BTMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with MTEX at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MTEX ACTIVE Mannatech Incorporated	E	33/100	—	74.9%	-35.0%	-2.23%	$16.1M	Benchmark Subject
BON Bon Natural Life Limited (Class A)	D	45/100	—	20.8%	—	-0.01%	$9.2M	/bon-vs-mtex →
NAII Natural Alternatives International Inc.	E	34/100	—	7.2%	-10.8%	-4.31%	$6.9M	/naii-vs-mtex →
BTMD Biote Corp. (Class A)	C	62/100	—	—	85.0%	+1.74%	$42.0M	/btmd-vs-mtex →
FTLF FitLife Brands Inc.	D	48/100	11.7x	43.1%	5.4%	-4.70%	$74.3M	/ftlf-vs-mtex →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001056358

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mannatech Incorporated (MTEX) reported GAAP revenue of $108.0M (-8.3% vs. FY2024 revenue of $117.9M , and -18.1% cumulative change since FY2023) , GAAP net income of -$15.2M, operating cash flow of -$3.0M, and free cash flow of -$4.3M (-319.8% YoY). On the balance sheet, MTEX closed FY2025 with $30.0M in total assets against $0 in total debt (Altman Z-Score: 3.25, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$108.0M	-$15.2M	-$3.0M	-$4.3M	$30.0M	—
FY2024 (FY)	2024-12-31	$117.9M	$2.5M	$2.3M	$2.0M	$36.1M	—
FY2023 (FY)	2023-12-31	$132.0M	-$2.2M	-$2.4M	-$2.4M	—	—

3. MTEX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MTEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Mannatech Incorporated (NASDAQ: MTEX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $8.33 (-2.23% 1D, market cap $16.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MTEX ranks #878 in composite RQD confidence.

How does MTEX compare to BON and NAII in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), MTEX carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 74.9%, and ROIC of -35.0%. By comparison, BON (Bon Natural Life Limited (Class A)) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $9.2M) and NAII (Natural Alternatives International Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -10.8%, cap $6.9M). Among the 5-stock peer group, FTLF leads on earnings multiple (11.7x) while BTMD leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MTEX?

Per MTEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001056358), Mannatech Incorporated generated $108.0M in revenue (-8.3% YoY), -$15.2M in net income, and -$4.3M in free cash flow against $30.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MTEX trading relative to its 50-day, 200-day, and 52-week technical levels?

MTEX last traded at $8.33 (-2.23% on volume of 34,595 shares), positioning the stock +8.32% above its 50-day simple moving average ($7.69) and +32.43% above its 200-day simple moving average ($6.29). Across its 52-week range of $3.80 to $12.45, MTEX sits at the 52.4% percentile with a 14-day RSI of 56.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($7.29 to $9.37).